China State Council Assesses Healthcare Reform Implementation
This article was originally published in PharmAsia News
Executive Summary
The China State Council Office of Healthcare Reform recently held a meeting to discuss the establishment of the essential drug system and pilot reform for public hospitals, two crucial aspects of the reform. By year end, 30 percent of basic medical institutions will need to lay out their plans for implementing the essential drug system, including production, circulation, pricing, applications, and reimbursement. This will ensure lower prices of essential drugs as well as timely allocation of compensation for medical institutions. Public hospitals will need to explore separating management and administrative roles, as well as attracting private capital investment to develop a diversified medical system. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.